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PEYVANDI AND GARAGIOLA complications, patients are treated by means of regular infusions of plasma-derived or recombinant FVIII concentrates. There have been many advances to optimize and ensure the safety and effectiveness of FVIII concentrates during the last 30 years, after the successful control of complications caused by such bloodborne pathogens as HIV and hepatitis C. 5 However, these improvements are darkened by a serious complication, ie, inhibitor development, recorded in more than 30% of severely affected patients within their initial [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] exposure days (EDs) to administered FVIII. The risk of inhibitor development is greatest in previously untreated patients (PUPs) and is strongly associated with the severity of the disease. FVIII inhibitors consist of a polyclonal population of antibodies, mainly IgG4, IgG1, and IgG2 subclasses that target multiple antigenic sites within the A2, A3, and C2 domains of the FVIII protein. 6, 7 The appearance of these alloantibodies neutralizes the hemostatic effect of FVIII concentrates, rendering the management of bleeding episodes difficult.
The immunology of inhibitor development is complex and not 
| HISTORICAL OVERVIEW
A circulating inhibitor, called "anticoagulant," was identified for the first time in the 1940s in a patient affected with hemophilia. 12, 13 Three hours after the blood transfusions, the patient began to bleed continuously and the coagulation time remained markedly prolonged. 12, 13 Later, this inhibitor was shown to be a γ-globulin and to appear only after repeated transfusions of whole blood. 14, 15 Thus, the anticoagulant was suggested to be the result of an immunization of patients to the deficient factor. Only in the late 1960s to early 1970s was it recognized that circulating anticoagulants were antibodies which developed in patients with hemophilia in response to replacement therapy. 16 At that time, determinants of the occurrence of circulating anticoagulants in hemophilia were unknown. In addition, it was not clearly established whether the development of circulating anticoagulants was influenced by the quantity, type, or frequency of replacement therapy. 17 During these years hemophilic patients were receiving much more treatment than in previous early years due to the development of technologies able to separate FVIII from large pools of donor plasma that resulted in the availability of freeze-dried, lyophilized FVIII concentrates. However, there was no evidence that one type of FVIII concentrate was more prone than others to produce inhibitor. In the 1980s and 1990s, there was a considerable amount of controversy and debate on the risk of inhibitor formation associated with the type of plasma-derived FVIII products with different purity. In those early days, inhibitor incidence was low, corresponding to 6%-7% in patients treated exclusively with plasma cryoprecipitate and remained relatively low, around 9%-10%, in patients treated with intermediate-purity FVIII concentrates. [18] [19] [20] [21] [22] The introduction of viral inactivation steps to produce new plasmaderived products improved the safety by minimizing the potential of bloodborne pathogen transmission. However, these additional steps in the manufacturing process probably made plasma-derived products more immunogenic with a higher risk of inhibitors which was estimated up to 20%-25%. [23] [24] [25] [26] [27] For instance, the introduction of a pasteurized version of a previously dry-heated FVIII concentrate in order to obtain a higher purity concentrate (CPS-P) was associated with an outbreak of inhibitors in multi-transfused patients in the Netherlands and Belgium. 28, 29 The heat-treated product was associated with a rate of new inhibitor development of 4.4/1000 patient-years, which increased to 20.1/1000 patient-years with the new pasteurized product. 28, 29 The authors concluded that the complex process of FVIII purification and viral inactivation, such as pasteurization and solvent-detergent treatment, may have altered the molecule, provoking inhibitor development.
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| IMPACT OF RECOMBINANT PRODUCTS: FROM OBSERVATIONAL TO RANDOMIZED STUDIES
The subsequent novel availability of recombinant FVIII concentrates in the early 1990s has added another variable to the issue of inhibitor risk. These preparations, derived from nonhuman mammalian cell lines, are associated with changes in the posttranslational processing or tertiary structure of FVIII that may lead to the formation of neoantigens and make these preparations more immunogenic than plasma-derived FVIII products.
The safety and efficacy of recombinant FVIII products were primarily tested in previously treated patients (PTPs, ie, patients having at least 150 EDs) for bleeding episodes, as requested by the guidelines for marketing authorization. These studies also evaluated the risk of inhibitor formation and indicated that in PTPs recombinant FVIII products were no more immunogenic than plasma-derived FVIII. 30, 31 However, PTPs are at a much lower risk of inhibitor development than PUPs. [30] [31] [32] [33] In the first few studies designed to evaluate safety, efficacy, and inhibitor risk of recombinant FVIII concentrates in PUPs, all the investigated products were well tolerated and not associated with significant adverse events, and the responses to treatment were excellent. However, the cumulative incidence of inhibitors was high, varying between 25% and 30%. [30] [31] [32] [33] In the next few years, some evidence emerged that different FVIII preparations had different degrees of immunogenicity, and a number of reports showed a lower rate of inhibitors in PUPs treated with plasma-derived products than with recombinant products. The cumulative risk of inhibitor development ranged from 20% to 33% in PUPs treated with various plasma-derived products. 34, 35 In contrast, patients treated with a single plasmatic concentrate had a cumulative incidence ranging from 10% to 12.4%, 19, 23 whereas inhibitor development in patients treated with a single recombinant product was much higher, ranging from 27.6% to 36%. 32, [36] [37] [38] [39] Strong clinical support to the view that plasmatic FVIII concentrates are less immunogenic than recombinant FVIII was provided in 2003 by a systematic review on the epidemiology of FVIII inhibitors. 40 In an analysis of 801 PUPs in the frame of 13 observational studies originally carried out to evaluate the efficacy and safety of an array of FVIII products, the risk of inhibitor development was more than double in patients treated with recombinant FVIII as opposed to plasma-derived products. 41 However, two subsequent multicenter observational studies, the CANAL (Concerted Action on Neutralizing Antibodies in severe haemophiLia A) study (316 PUPs) 42 
and the larger RODIN (Research Of Determinants of
INhibitor development) cohort study (574 PUPs) 43 showed no difference in immunogenicity between plasma-derived and recombinant FVIII products. Unexpectedly the RODIN study also reported that second-generation full-length recombinant products were associated with an increased risk of inhibitor as compared with thirdgeneration products (adjusted hazard ratio 1.60; 95% CI, 1.08-2.37).
Subsequently, this higher immunogenicity observed for secondgeneration full-length recombinant products was confirmed in a cohort of patients included in the Rèseau FranceCoag and in the UK children registered in the UKHCDO National Haemophilia Database (NHD) and most recently in the FranceCoag PUP cohort. [44] [45] [46] Two additional studies, the EUHASS study 47 and a Canadian cohort study, 48 who also investigated the higher immunogenicity of the second-generation recombinant products, did not confirm the RODIN data, but were small or did not inform adjustment for confounding. Subsequently, an attempt was made to reconcile these contrasting results. Some meta-analysis and systematic reviews, based also on data from individual observational studies, reported a higher risk of inhibitor development with recombinant FVIII than with plasma-derived FVIII, although the difference were attenuated after adjustment for confounders. [49] [50] [51] It must be kept in mind that all observational studies may suffer from confounding by indication, ie, when the choice of product class was made on the basis of treaters' perception of inhibitor risk.
To sum up, observational studies, meta-analysis, and systematic reviews suggested the existence of a difference between plasma-derived and recombinant FVIII products and that plasmaderived products determine a lower incidence of inhibitors, but due to confounding these results were not conclusive. For instance, in a debate article on the question whether the rate of inhibitors was higher with recombinant or plasma-derived products, the author stated that "it is unlikely that in the near future we will have sufficient prospective randomized studies to resolve definitively the dilemma of inhibitor induction." 52 This statement highlights the complexity to carry out a randomized clinical trial but also its need in order to obtain final and conclusive results on the major current complication of hemophilia therapy.
With this background and gaps of knowledge, the first randomized study contrasting plasma-derived and recombinant FVIII products, the Study on Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) trial was started in 2010 and published in 2016. 53 The study included 251 previously untreated hemophilia A boys (<6 years) randomly assigned to receive a VWF-containing plasma-derived FVIII product or a recombinant FVIII product and followed for inhibitor development for 50 52 showing that the class of recombinant FVIII products was associated with an 87% higher incidence of inhibitor than plasma-derived FVIII products. 53 These data created a debate within the hemophilia treatment community on the clinical consequences of the outcome of SIPPET. 54 In addition, a few post hoc analyses of SIPPET provided additional data.
For instance, the rate of inhibitor incidence was evaluated over time every 5 EDs (from 0 to 50 EDs) in hemophilia patients treated with different classes of FVIII products. 55, 56 The highest rates of inhibitor occurrence were developed in the first 10 EDs, with a great contrast between recombinant and plasma-derived FVIII during the first 5
EDs: hazard ratio 3.14 (95% CI, 1.01-9.74) for all inhibitors and 4.19 (95% CI, 1.18-14.8) for high-titer inhibitors. For patients treated with plasma-derived FVIII, the peak of inhibitor development occurred later (6-10 EDs) and was of shorter duration. These results emphasize once again the high immunologic vulnerability of patients during the earliest exposure to FVIII but also the strongest response to recombinant FVIII products. 56 Finally, it must be mentioned that most recently Calvez et al. 46 reported data from a French national cohort study concordant with findings from the SIPPET randomized trial, ie, a higher risk of inhibitor development in patients treated with recombinant than with plasma-derived products (1.64; 95% CI, 0.82-3.25).
| ENVIRONMENTAL RISK FACTORS
| Age, treatment regimen, and intensity of treatment
The possible role played by other environmental risk factors in inhibitor development, such as age at first treatment, type of treatment regimen, and intensity of treatment, has been extensively discussed.
Additional risk factors such as severity of bleeds, surgery, concomitant infections, or vaccinations have also been implicated in the context of concurrent immunological danger signals resulting in immune reactions in association with FVIII administration (Figure 1 ).
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The age at which to initiate therapy is a debated matter. In the early 2000s, Lorenzo et al. showed that the incidence of inhibitors was higher in patients initiating therapy before the age of 6 months than for older pediatric patients. 34 In keeping with this study, van der Bom et al. confirmed the role of first treatment at an early age in the development of inhibitors, with a cumulative incidence at 100
EDs of 34% (95% CI 7%-61%) in patients starting therapy before the age of 6 months and 13% (0%-27%) in those starting between 1 and 1.5 years. 57 These observations were consistent with subsequent findings by Santagostino et al. in patients who had their first treatment before the age of 11 months, an effect, however, that was attenuated after adjustment for FVIII genetic risk factors. 58 Subsequently, a multivariate analysis, conducted in the frame of a French cohort of patients with severe hemophilia, showed a threefold difference in inhibitor risk between children treated for the first time before 6 months of age compared to those treated after 12 months of age. 59 Furthermore, the data published in the CANAL study demonstrated that the rate of inhibitor was associated with age at first treatment, diminishing from 41% for patients treated within the first months of age to 18% in those treated after 18 months, but this association largely vanished after adjustment for Confounders. 42 In a report by Chalmers et al., 60 the exposure to FVIII throughout the neonatal period showed no association with a higher incidence of inhibitors than in patients treated later during the first year of life. Two additional studies published most recently found no association between age of therapy initiation and inhibitor formation during the first years of life. 46, 61 To sum up, the data reported in the literature are discordant, in all likelihood owing to the observational nature of the studies, and thus fail to support firmly the hypothesis that a first replacement therapy at an early age increases the risk of inhibitor formation.
The role of prophylaxis has also been examined as a potential risk factor in the development of inhibitors. In the frame of the CANAL study, Gouw et al. showed that prophylaxis was associated with a decreased inhibitor risk as compared with on-demand treatment, 42 but the subsequent case-control study of the UKHCDO did not confirm the protective role of prophylactic regimens. 62 In a pilot study 65 In these studies, a low inhibitor incidence during prophylaxis was explained as an immune tolerance upon exposure to infused FVIII. Cumulatively, the data of the literature on the issue of the protective effect of prophylaxis on inhibitor formation appear still inconclusive.
The intensity of FVIII treatment covers a spectrum of determinants including peak treatment moments of intense exposure, defined as ≥5 consecutive days with treatment as first exposure or anytime in the first 50 EDs. In the multicenter CANAL cohort study, peak treatment moments at the time of first treatment was associated with a 3.3-fold (95% CI, 2.1-5.3) higher risk of inhibitor development than in patients who received treatment with more days elapsing between each treatment. 42 In keeping with the CANAL study, a multicenter cohort study showed that patients who had a major peak treatment moment at the time of the first treatment had a 2.1 (95% CI, 1.0-4.5) times higher risk of inhibitor onset than those who only had a treatment on a single day or two consecutive days. 66 In addition, the effect of peak treatment moments was also estimated at any exposure day during the first 50 EDs. Peak treatment moments of three or five consecutive days at any exposure day again increased the risk of inhibitor development, but less markedly (RR 1.6; CI, 1.0-2.6). 67 Maclean et al., 62 in a multicenter casecontrol study of the UK Haemophilia Centre Doctors' Organization (UKHCDO), reported that peak treatment moments major than five consecutive days at any time during early exposure had the effect to increase the inhibitor risk (OR: 2.7, CI, 1.4-5.4). This finding was confirmed in patients with peak treatment moments of 10 EDs or more (OR: 5.5, CI, 1.5-20), whereas peaks of 3 EDs were not associated with an increased risk (OR: 0.9, CI, 0.5-1.8).
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In a systematic review by Eckhardt et al., 67 the findings of the three aforementioned studies were pooled. Peak treatment To sum up, there is agreement between the available studies that peak treatment moments are associated with an increased risk of inhibitor development and that this effect is stronger when the peak treatment occurred at first exposure.
| Immune system and danger signal
Over the last few years, a commonly suggested explanation for the environment-related inhibitor risk is the danger signal effect. [9] [10] [11] The danger theory, which appeared in 1994, proposes that the immune system is more worried about damage than foreignness, and is brought into action by alarm signals from injured tissues rather than by the recognition of nonself. 68 The danger model asserts that the immune system is activated by danger signals from injured cells, such as those exposed to pathogens, toxins, and mechanical damage. 69 In hemophilia, the innate immune response becomes activated, with up-regulation of a response to FVIII. 70 Thus, tissue injury may clarify, partially, the increased inhibitor incidence after periods with intensive treatment.
| Surgery
Surgery is characterized by tissue damage with the related release of endogenous danger signals that could potentially promote inhibitor development. A case-control study by Santagostino et al.
in 2005 found no association between surgery and risk of inhibitor development, but the study was too small to lead to definitive conclusions. 58 In contrast, the CANAL study reported that surgical procedures carried an increased inhibitor risk 42 and a subsequent meta-analysis of four studies by Eckhardt et al. 67 showed that the risk of inhibitor development after surgery at first treatment with FVIII was evidently associated with a heightened risk, with a pooled OR of 4.1 (95% CI, 2.0-8.4) compared with FVIII first treatment for other reasons (ie, bleeding or prophylaxis). 67 Nevertheless, the RODIN study showed that surgery at first treatment does not cause an increased inhibitor risk (adjusted RR, 1.2; 95% CI, 0.54-2.6). In summary, surgery has been associated in some studies with inhibitor formation but heterogeneity in type of surgery, and duration and doses of FVIII treatments might justify the differences between some of them. 72 The research on the impact of vaccination on inhibitor development is still preliminary, and no definitive conclusions can be drawn.
| Vaccinations
| Infections
Few studies have investigated the effect of infections on inhibitor development, and thus conclusions are often difficult to draw.
In recent years, there has been substantial progress in the understanding of the complexity of the host-microbiota relationship and its effects on human health. 73 75 but these data are still preliminary.
| CONCLUSION
The most important modifiable risk factor for inhibitor development in PUPs is the treatment with a FVIII concentrate. Therefore, the choice of the least immunogenic FVIII product during the first 10
EDs is crucial. 55, 56 
| FUTURE PERSPECTIVES
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